<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Within the framework of the GIMEMA Study Group, the characteristics of <z:hpo ids='HP_0006721'>acute lymphoid leukemia</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> occurring in patients who have suffered a previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> were studied </plain></SENT>
<SENT sid="1" pm="."><plain>Assessment was also made of the clinical course, laboratory features and overall outcome of these conditions </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: A four-year, multi-center retrospective study was conducted to evaluate the effect of treatment for previous <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e> on the development of secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The study collected in the GIMEMA Archive of Adult <z:hpo ids='HP_0002488'>Acute Leukemia</z:hpo> 3934 new cases of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (2964 AML, 901 ALL, 60 <z:hpo ids='HP_0005531'>acute biphenotypic leukemia</z:hpo>) </plain></SENT>
<SENT sid="4" pm="."><plain>Among these cases, data were evaluated from patients with a personal history of a previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, and included inquiring into demographic data, history of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">neoplastic diseases</z:e> in the 1st degree relatives, type and treatment of the previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, latency until the development of a secondary <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> diagnosis, laboratory features, treatment and outcome at the <z:hpo ids='HP_0003674'>onset</z:hpo> of secondary <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Approximately 200 (5.1%) patients presented a previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Twenty-one were affected by ALL and 179 by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The proportion of patients with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> was higher than that of patients with secondary ALL (179/2964 vs 21/901, O.R </plain></SENT>
<SENT sid="8" pm="."><plain>2.69-95% C.I </plain></SENT>
<SENT sid="9" pm="."><plain>1.66-4.39, P&lt;0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>The median latency, from the <z:hpo ids='HP_0003674'>onset</z:hpo> of the previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> to the development of secondary ALL was 27 months and to the development of <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> was 52 months (P&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>Furthermore, of patients who previously received chemotherapy more developed a second <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (66/127 sAML vs 5/21 sALL; O.R </plain></SENT>
<SENT sid="12" pm="."><plain>3.46-95% C.I </plain></SENT>
<SENT sid="13" pm="."><plain>1.10-11.56, P&lt;0.01) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: In most cases, chemotherapy treatment for a previous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> can play a role in the development of <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>In almost <z:hpo ids='HP_0000001'>all</z:hpo> cases of secondary ALL, the role of previous drugs does not appear to be relevant </plain></SENT>
<SENT sid="16" pm="."><plain>On the basis of our analysis, performed systematically for the first time on a large adult series of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, we conclude that in these patients a biological predisposition to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> may be suspected </plain></SENT>
</text></document>